Cargando…

Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling

BACKGROUND: Liver fibrosis is the consequence of diverse liver injuries and can eventually develop into liver cirrhosis. Ginkgo biloba extract (GBE) is an extract from dried ginkgo leaves that has many pharmacological effects because of its various ingredients and has been shown to be hepatoprotecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuanyuan, Wang, Rong, Wang, Yujie, Peng, Ruqin, Wu, Yan, Yuan, Yongfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671772/
https://www.ncbi.nlm.nih.gov/pubmed/26664050
http://dx.doi.org/10.2147/DDDT.S93732
_version_ 1782404455380025344
author Wang, Yuanyuan
Wang, Rong
Wang, Yujie
Peng, Ruqin
Wu, Yan
Yuan, Yongfang
author_facet Wang, Yuanyuan
Wang, Rong
Wang, Yujie
Peng, Ruqin
Wu, Yan
Yuan, Yongfang
author_sort Wang, Yuanyuan
collection PubMed
description BACKGROUND: Liver fibrosis is the consequence of diverse liver injuries and can eventually develop into liver cirrhosis. Ginkgo biloba extract (GBE) is an extract from dried ginkgo leaves that has many pharmacological effects because of its various ingredients and has been shown to be hepatoprotective. PURPOSE AND METHODS: Aimed to investigate the underlying protective mechanisms of GBE on carbon tetrachloride (CCl(4))-induced liver fibrosis in rats. Male Sprague Dawley rats were randomly divided into four groups: control group (C), model group (M), low-dose group (L), and high-dose group (H). Liver fibrosis was induced by CCl(4) groups M, L, and H: group C was administered saline. In addition, GBE at different doses was used to treat groups L and H. RESULTS: The results of hematoxylin and eosin staining, Masson’s trichrome staining, a liver function index, and a liver fibrosis index showed that GBE application noticeably mitigated fibrosis and improved the function of the liver. The western blotting and immunohistochemistry analyses indicated that GBE reduced liver fibrosis not only by inhibiting p38 MAPK and NF-κBp65 via inhibition of IκBα degradation but also by inhibiting hepatocyte apoptosis via downregulation of Bax, upregulation of Bcl-2, and subsequent inhibition of caspase-3 activation. Inflammation-associated factors and hepatic stellate cell (HSC)-activation markers further demonstrated that GBE could effectively inhibit HSC activation and inflammation as a result of its regulation of p38 MAPK and nuclear factor-kappa B/IκBα signaling. CONCLUSION: Our findings indicated a novel role for GBE in the treatment of liver fibrosis. The potential mechanisms may be associated with the following signaling pathways: 1) the p38 MAPK and nuclear factor-kappa B/IκBα signaling pathways (inhibiting inflammation and HSCs activation) and 2) the Bcl-2/Bax signaling pathway (inhibiting the apoptosis of hepatocytes).
format Online
Article
Text
id pubmed-4671772
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46717722015-12-09 Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling Wang, Yuanyuan Wang, Rong Wang, Yujie Peng, Ruqin Wu, Yan Yuan, Yongfang Drug Des Devel Ther Original Research BACKGROUND: Liver fibrosis is the consequence of diverse liver injuries and can eventually develop into liver cirrhosis. Ginkgo biloba extract (GBE) is an extract from dried ginkgo leaves that has many pharmacological effects because of its various ingredients and has been shown to be hepatoprotective. PURPOSE AND METHODS: Aimed to investigate the underlying protective mechanisms of GBE on carbon tetrachloride (CCl(4))-induced liver fibrosis in rats. Male Sprague Dawley rats were randomly divided into four groups: control group (C), model group (M), low-dose group (L), and high-dose group (H). Liver fibrosis was induced by CCl(4) groups M, L, and H: group C was administered saline. In addition, GBE at different doses was used to treat groups L and H. RESULTS: The results of hematoxylin and eosin staining, Masson’s trichrome staining, a liver function index, and a liver fibrosis index showed that GBE application noticeably mitigated fibrosis and improved the function of the liver. The western blotting and immunohistochemistry analyses indicated that GBE reduced liver fibrosis not only by inhibiting p38 MAPK and NF-κBp65 via inhibition of IκBα degradation but also by inhibiting hepatocyte apoptosis via downregulation of Bax, upregulation of Bcl-2, and subsequent inhibition of caspase-3 activation. Inflammation-associated factors and hepatic stellate cell (HSC)-activation markers further demonstrated that GBE could effectively inhibit HSC activation and inflammation as a result of its regulation of p38 MAPK and nuclear factor-kappa B/IκBα signaling. CONCLUSION: Our findings indicated a novel role for GBE in the treatment of liver fibrosis. The potential mechanisms may be associated with the following signaling pathways: 1) the p38 MAPK and nuclear factor-kappa B/IκBα signaling pathways (inhibiting inflammation and HSCs activation) and 2) the Bcl-2/Bax signaling pathway (inhibiting the apoptosis of hepatocytes). Dove Medical Press 2015-12-03 /pmc/articles/PMC4671772/ /pubmed/26664050 http://dx.doi.org/10.2147/DDDT.S93732 Text en © 2015 Wang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Wang, Yuanyuan
Wang, Rong
Wang, Yujie
Peng, Ruqin
Wu, Yan
Yuan, Yongfang
Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling
title Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling
title_full Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling
title_fullStr Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling
title_full_unstemmed Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling
title_short Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling
title_sort ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 mapk, nf-κb/iκbα, and bcl-2/bax signaling
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671772/
https://www.ncbi.nlm.nih.gov/pubmed/26664050
http://dx.doi.org/10.2147/DDDT.S93732
work_keys_str_mv AT wangyuanyuan ginkgobilobaextractmitigatesliverfibrosisandapoptosisbyregulatingp38mapknfkbikbaandbcl2baxsignaling
AT wangrong ginkgobilobaextractmitigatesliverfibrosisandapoptosisbyregulatingp38mapknfkbikbaandbcl2baxsignaling
AT wangyujie ginkgobilobaextractmitigatesliverfibrosisandapoptosisbyregulatingp38mapknfkbikbaandbcl2baxsignaling
AT pengruqin ginkgobilobaextractmitigatesliverfibrosisandapoptosisbyregulatingp38mapknfkbikbaandbcl2baxsignaling
AT wuyan ginkgobilobaextractmitigatesliverfibrosisandapoptosisbyregulatingp38mapknfkbikbaandbcl2baxsignaling
AT yuanyongfang ginkgobilobaextractmitigatesliverfibrosisandapoptosisbyregulatingp38mapknfkbikbaandbcl2baxsignaling